DEFA14A: Keros Therapeutics Urges Stockholders to Vote for Director Nominees Amid Strategic Review

Keros Therapeutics files investor presentation and issues open letter to stockholders, urging them to vote for the company's director nominees amidst a strategic review process and a campaign by ADAR1 Capital Management.

Summary

• Keros Therapeutics is urging stockholders to vote for its director nominees at the upcoming Annual Meeting on June 4, 2025.
• The company is currently undergoing a strategic review process to maximize stockholder value, with an interim update expected by June 9, 2025.
• The review includes potential options such as a sale of the company, continued investment in the pipeline, or return of excess capital.
• ADAR1 Capital Management is running a campaign to influence the strategic review, which Keros believes is self-serving and not in the best interests of all stockholders.
• Keros highlights its differentiated clinical pipeline, including KER-065 for neuromuscular diseases, elritercept (KER-050) for cytopenias, and cibotercept (KER-012) for pulmonary arterial hypertension.
• The company emphasizes the $200 million upfront payment and potential $1.1 billion in milestones from its collaboration with Takeda for elritercept.
• Keros plans to initiate a Phase 2 clinical trial of KER-065 in patients with Duchenne muscular dystrophy (DMD) in the first quarter of 2026, subject to regulatory interactions.
• Topline data from the Phase 2 clinical trial of cibotercept in patients with pulmonary arterial hypertension (PAH) is expected in the second quarter of 2025.
• The Keros Board consists of nine directors, with a majority being independent, and includes representatives of major stockholders.
• Keros believes its board has the right expertise to oversee the strategic review process and execute the value-maximizing path forward.

Sentiment

Score: 6

Explanation: The document conveys a mixed sentiment. While Keros highlights its pipeline and Takeda partnership, the ongoing strategic review and the conflict with ADAR1 introduce uncertainty. The emphasis on maximizing stockholder value suggests potential positive outcomes, but the risks associated with clinical trials and regulatory approvals temper the overall outlook.

Positives

• Keros is undergoing a strategic review to maximize stockholder value.
• The company has a $200 million upfront payment and potential $1.1 billion in milestones from the Takeda partnership.
• Keros has a differentiated clinical pipeline with promising product candidates.
• The company has a seasoned management team with extensive experience.
• The Keros Board is comprised of experienced and independent directors.

Negatives

• ADAR1 Capital Management is running a campaign against the company, potentially disrupting the strategic review process.
• The TROPOS trial for cibotercept was terminated early due to safety concerns.
• The company faces risks and uncertainties related to clinical trials, regulatory approvals, and competition.

Risks

• The strategic review process may not achieve the desired objectives.
• The company may face difficulties in retaining key personnel and maintaining relationships with partners.
• Clinical trials may be delayed or unsuccessful.
• The company may face competition from third parties.
• Keros may need to raise additional funding to complete the development and commercialization of its product candidates.

Future Outlook

Keros expects to provide an interim update on the Strategic Committee's work no later than June 9, 2025. The company plans to advance KER-065 into a Phase 2 clinical trial in DMD in the first quarter of 2026, subject to regulatory interactions. Topline data from the Phase 2 clinical trial evaluating cibotercept in patients with pulmonary arterial hypertension (PAH) is expected in the second quarter of 2025.

Management Comments

• Our Board of Directors (the Board) is focused on acting in the best interests of the Company and its stockholders.
• We strongly recommend that you vote FOR each of Keros three highly qualified and experienced director nominees and protect the value of your investment.
• The Keros Board will continue to make decisions that are in the best interests of its stockholders to generate long-term value.

Industry Context

The announcement comes amid increased shareholder activism in the biotech industry, with companies facing pressure to maximize shareholder value through strategic reviews, mergers, or acquisitions. Keros's strategic review and response to ADAR1's campaign reflect this trend.

Comparison to Industry Standards

• The board composition of Keros, with 44% investor representation, is higher than the median of its performance peer group (~17%) and proxy peers (13%).
• The Takeda partnership, with a $200 million upfront payment and potential $1.1 billion in milestones, is comparable to other licensing deals in the biopharmaceutical industry.
• The strategic review process is similar to those undertaken by other biotech companies facing shareholder activism or seeking to maximize value.

Stakeholder Impact

• Shareholders are impacted by the strategic review process and the outcome of the vote on director nominees.
• Employees are impacted by the potential changes resulting from the strategic review.
• Patients may benefit from the development of Keros's product candidates.
• Takeda is impacted by the collaboration agreement for elritercept.

Next Steps

• Stockholders to vote on director nominees at the Annual Meeting on June 4, 2025.
• Keros to provide an interim update on the strategic review process by June 9, 2025.
• Keros to engage with regulatory authorities on the KER-065 program in the third quarter of 2025.
• Keros to initiate a Phase 2 clinical trial of KER-065 in patients with DMD in the first quarter of 2026, subject to regulatory interactions.
• Keros to present topline data from the Phase 2 clinical trial evaluating cibotercept in patients with pulmonary arterial hypertension (PAH) in the second quarter of 2025.

Key Dates

Keywords

Keros Therapeutics, strategic review, director nominees, ADAR1 Capital Management, elritercept, KER-065, cibotercept, stockholder value, clinical trials, Takeda